Skip to main content

MYLAN 2045 MYLAN 2045 (Tacrolimus 0.5 mg)

Pill with imprint MYLAN 2045 MYLAN 2045 is Orange / Gray, Capsule-shape and has been identified as Tacrolimus 0.5 mg. It is supplied by Mylan Pharmaceuticals Inc..

Tacrolimus is used in the treatment of organ transplant, rejection reversal; organ transplant, rejection prophylaxis and belongs to the drug class calcineurin inhibitors. Risk cannot be ruled out during pregnancy. Tacrolimus 0.5 mg is not a controlled substance under the Controlled Substances Act (CSA).

Images for MYLAN 2045 MYLAN 2045


MYLAN 2045 MYLAN 2045
0.5 mg
Orange / Gray
14.00 mm
Prescription only
Drug Class
Calcineurin inhibitors
Pregnancy Category
C - Risk cannot be ruled out
CSA Schedule
Not a controlled drug
Labeler / Supplier
Mylan Pharmaceuticals Inc.
Inactive Ingredients
lactose anhydrous, ferrosoferric oxide, silicon dioxide, croscarmellose sodium, gelatin, hypromelloses, lactose monohydrate, magnesium stearate, sodium lauryl sulfate, titanium dioxide, ferric oxide yellow, D&C Red No. 28, D&C Yellow No. 10, FD&C Red No. 40, FD&C Blue No. 1, FD&C Blue No. 2, propylene glycol, shellac

Note: Inactive ingredients may vary.

Labelers / Repackagers

NDC Code Labeler / Repackager
00378-2045 (Discontinued) Mylan Pharmaceuticals Inc.
51079-0817 UDL Laboratories Inc.

Get help with Imprint Code FAQs.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.